Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.74 |
| ▸ | MGAM | O43451 | 5/20 | 0.74 |
| ▸ | CA12 | O43570 | 5/20 | 0.74 |
| ▸ | CA1 | P00915 | 5/20 | 0.74 |
| ▸ | CA2 | P00918 | 5/20 | 0.74 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.58 |
| ▸ | ACP1 | P24666 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGAV | P06756 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17309311 | 1.00 | CA9 (0.74) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL27618822 | 0.81 | MEN1 (0.67) | CA9ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL11329893 | 0.79 | CA9 (0.77) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL11329898 | 0.79 | CA9 (0.77) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL11334446 | 0.78 | CA9 (0.74) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL11334449 | 0.78 | CA9 (0.74) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL17295350 | 0.78 | CA9 (0.56) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL17295348 | 0.78 | CA9 (0.56) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL17295314 | 0.77 | MGAM (0.56) | CA9MGAMCA12CA1CA2 | |
| SCHEMBL17295313 | 0.77 | MGAM (0.56) | CA9MGAMCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | UNIVERSITAT BERN (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | SLC18A2, AANAT, CNR2 | CA9 4726/4885MGAM 4234/4885CA12 4748/4885 |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | SLC18A2, AANAT, CNR2 | CA9 4726/4885MGAM 4234/4885CA12 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.